12 signals · h1b_lca
Scores are directional signals derived from aggregated public data — not verified findings or investment advice. Methodology
Signal-based estimates from public data — not verified assessments. Learn more
Some stress signals present but below significant thresholds.
Low-to-moderate risk signals with no major red flags in current data.
Signal data from 2 sources places Foundation Medicine in the Genomic Medicine space at moderate workforce stress signals with low overall risk indicators.
Signals for Foundation Medicine were collected from 2 sources. Aggregate signal sentiment appears broadly positive. The stress score stands at 37/100 with a risk score of 25/100. These findings are based on a limited number of signals and may not be fully representative.
Foundation Medicine acquires SAGA Diagnostics in a deal worth up to $595 million Biostock
Molecular insights for cancer treatment decisions.
Based on 12 signals across 1 source · snapshot 9 Jul 2026
Moderate — directional but may shift as more signals arrive.
Overall community sentiment for Foundation Medicine is positive based on public signals as of 9 Jul 2026.
Based on 12 signals across 1 source
Scores are directional signals derived from public data — not certified assessments or recommendations. Confidence indicates data coverage, not accuracy. Learn how scores are calculated →
Derived from public sources such as news, filings, and reported events.
What this means
Signals suggest a mixed picture — review the evidence below for context.
AI-generated from public signals — may be incomplete. Based on 3 recent signals.
This summary is generated from publicly available review and signal data. It is intended as an indicative overview only and should not be used as the sole basis for employment, investment, or business decisions. Signal volume and source diversity may limit representativeness.
AI summaries are generated from public signals and may not reflect the full picture.
Sciety portfolio company Saga Diagnostics acquired by Foundation Medicine, a subsidiary of Roche Cision News